Journal
TISSUE ANTIGENS
Volume 62, Issue 4, Pages 273-284Publisher
BLACKWELL MUNKSGAARD
DOI: 10.1034/j.1399-0039.2003.00143.x
Keywords
cancer; expression regulation; HLA; HLA-G; immune inhibition; pregnancy; tolerance
Categories
Ask authors/readers for more resources
In 1998, the first International Conference on human leukocyte antigen-G (I-MA-G) was held in Paris. At that time, HLA-G was still a new HLA class I molecule, few aspects of its immunological functions were known, and its expression by tumors was just being described. In 1998, tools to properly study HLA-G were lacking, especially monoclonal antibodies, and three conclusions were drawn after the congress: (i) animal models were needed, (ii) the biology of HLA-G isoforms had to be confirmed, and (iii) HLA-G expression by tumors required clarification. Five years later, these three issues have been addressed. HLA-G is now gaining pace and is investigated for its immuno-inhibitory functions in the context of multiple pathologies. Eighty five oral presentations were given this year for more than 200 investigators working on HLA-G by speakers from over 20 countries. The success of the 3rd International Conference on HLA-G reflects the interest and tremendous work of the many research teams which, over the years, contributed to the publication of more than 500 peer-review articles. We summarize the key points that were presented and discussed during this meeting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available